Loading...
Loading...
WVE| Name | Value |
|---|---|
| Revenues | 83.7M |
| Cost of Revenue | 0.0M |
| Gross Profit | 83.7M |
| Operating Expense | 60.8M |
| Operating I/L | 23.0M |
| Other Income/Expense | 6.3M |
| Interest Income | 0.0M |
| Pretax | 29.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 29.3M |
Wave Life Sciences Ltd. is a clinical stage genetic medicine company that focuses on designing, optimizing, and producing novel stereopure oligonucleotides through its PRISM platform. The company develops oligonucleotides that target ribonucleic acid to reduce the expression of disease-promoting proteins, restore the production of functional proteins, or modulate protein expression. Its product pipeline includes treatments for amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, Duchenne muscular dystrophy, spinocerebellar ataxia 3, and various CNS disorders. Additionally, Wave Life Sciences is working on GalNAc-conjugated AIMers for hepatic indications and preclinical programs for retinal diseases. The company has collaboration agreements with several prominent organizations.
